Aptevo Therapeutics share price logo

Aptevo Therapeutics

NASDAQ: APVO

$1.79

-0.01

(-0.56%)

as on

Aptevo Therapeutics Stock Performance

as on October 10, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $1.78
    $1.81
    downward going graph

    0.56%

    Downside

    1.12%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $1.37
    $31.14
    downward going graph

    23.46%

    Downside

    1639.56%

    Upside

    downward going graph

Aptevo Therapeutics share price movements today

Previous Close
$1.80
Open
$1.79
Volume
55.5K
Market Cap
$3.3M
Day's Low - High
$1.78 - $1.81
52 Week Low - High
$1.37 - $31.14

Aptevo Therapeutics Historical Returns

1 Month Return
-2.19 %
3 Month Return
-54.57 %
1 Year Return
-93.67 %
3 Year Return
-100 %
5 Year Return
-100 %

Aptevo Therapeutics Stock Fundamentals & Key Indicators

Check Aptevo Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$3.3M

EPS (TTM)

-211.18

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.01

Industry PE ratio

-3.02

PEG Ratio

-0.00

EBITDA

-26.4M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-201.49%

Aptevo Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Aptevo Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Buy$3.3M-100.00%-0.010.00%0.00%
Neutral$78.6B-26.21%-24.69-12.57%0.00%
StrongBuy$127.6B185.06%29.0686.04%0.00%
Buy$76.4B35.73%17.6684.86%0.50%

Stock Returns calculator for Aptevo Therapeutics Stock including INR - Dollar returns

The Aptevo Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Aptevo Therapeutics investment value today

Current value as on today

₹6,907

Returns

-₹93,093

(-93.09%)

Returns from Aptevo Therapeutics Stock

-₹93,666 (-93.67%)

Dollar Impact

₹573 (+0.57%)

Analyst Recommendation on Aptevo Therapeutics Stock

Based on 8 analysts

BUY

87.50%

Buy

12.50%

Hold

0.00%

Sell

Based on 8 analysts, 87.5% of analysts recommend a 'BUY' rating for Aptevo Therapeutics. Average target price of $25.5

Aptevo Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Aptevo Therapeutics.

What analysts predicted

92.98%UPSIDE

Target Price

$25.5

Current Price

$1.79

Analyzed by

8 Analysts

Target

$25.50

Aptevo Therapeutics target price $25.5, a slight upside of 92.98% compared to current price of $1.79. According to 8 analysts rating.

Indian Investors' Interest in Aptevo Therapeutics Stock

Search interest for Aptevo Therapeutics Stock has decreased by -23% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-23% versus previous 30 day period

Aptevo Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
-
-
-
-
-
-
-
-
-
-
Gross Profit
0
-
-
0
-
-
-
0
0
-
Operating Income
-6
-6
-5
-6
-6
-6
-7
-5
-6
-6
EBITDA
-6
-5
-5
-6
-6
-6
-7
-5
-6
-6
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-6
-5
-5
-6
-6
-6
-7
-5
-6
-6
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-6
-5
-5
-6
-6
-6
-7
-5
-6
-6
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Aptevo Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Mar 2021
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
14
23
-
4
12
3
-
-
-
Gross Profit
9
11
-2
-13
12
3
-
0
0
Operating Income
-53
-51
-40
-27
-21
-28
-28
-24
-26
EBITDA
-50
-49
-40
-26
-28
7
-18
-23
-25
Interest Expense
-
-
-
-
-
-
-
-
-
Depreciation
3
2
2
1
1
0
0
0
0
Income Before Tax
-55
-53
-43
-30
-29
7
-18
-24
-25
Income Tax Expense
-23
-
-
-
-
-
-
-
-
Net Income
6
-53
-44
-17
-28
8
-17
-24
-25
Net Profit Margin
65.82%
51.39%
0.00%
-314.30%
100.00%
100.00%
0.00%
0.00%
0.00%

Aptevo Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-6
-5
-5
-6
-6
-6
-7
-5
-6
-6
Operating Cash Flow
-6
-6
-5
-5
-6
-7
-6
-5
-7
-5
Investing Cash Flow
-
-
-
-
-
-
-
-
-
-
Financing Cash Flow
0
3
4
6
-
14
18
5
0
0
Change in Cash
-6
-2
0
0
-6
7
11
0
-7
-4

Aptevo Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Mar 2021
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
6
-53
-40
-17
-28
8
-17
-24
-25
Operating Cash Flow
-41
-51
-42
-29
-21
-21
-11
-23
-25
Investing Cash Flow
29
72
4
28
0
0
-
-
-
Financing Cash Flow
9
0
20
23
26
-2
5
15
38
Change in Cash
-2
20
-18
22
3
-23
-5
-8
12

Global Institutional Holdings in Aptevo Therapeutics

Check out the Institutions with significant holdings in Aptevo Therapeutics.

Funds
Holdings
VANGUARD INDEX FUNDS
0.70%
Vanguard
0.70%
Fidelity Concord Street Trust
0.53%

Aptevo Therapeutics News & Key Events

  • img

    Today's Timeline - 03 September

    Thu, 05:45 PM

    -

    Aptevo reports 93% clinical benefit rate for mipletamig in TP53-mutant AML patients, nearly doubling previous remission rates.

Insights on Aptevo Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 738.6% return, outperforming this stock by 832.3%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 119.0% return, outperforming this stock by 219.0%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 months, APVO stock has moved down by -54.6%

About Aptevo Therapeutics

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.
OrganisationAptevo Therapeutics
Headquarters2401 4th Avenue, Seattle, WA, 98121, US
IndustryBiotechnology
CEOJeffrey G. Lamothe

Key Management of Aptevo Therapeutics

Name

Title

Ms. Miriam Weber Miller

Vice President of Investor Relations & Corporate Communications

Dr. Dirk Huebner M.D.

Senior Vice President & Chief Medical Officer

Mr. Marvin L. White

Executive Chair

Mr. Jeffrey G. Lamothe CA

CEO, President & Director

Ms. SoYoung Kwon J.D., LL.M.

Corporate Secretary, Senior VP, General Counsel, Business Development & Corporate Affairs

Ms. Daphne L. Taylor CPA

Senior VP & CFO

Ms. Mary J. Janatpour Ph.D.

Senior VP & Chief Scientific Officer

FAQs

What is Aptevo Therapeutics share price today?

Aptevo Therapeutics share price today is $1.79 as on at the close of the market. Aptevo Therapeutics share today touched a day high of $1.81 and a low of $1.78.

What is the 52 week high and 52 week low for Aptevo Therapeutics share?

Aptevo Therapeutics share touched a 52 week high of $31.14 on and a 52 week low of $1.37 on . Aptevo Therapeutics stock price today i.e. is closed at $1.79,which is 94.25% down from its 52 week high and 30.66% up from its 52 week low.

What is Aptevo Therapeutics's market capitalisation today?

Aptevo Therapeutics market capitalisation is $0.00T as on .

How to invest in Aptevo Therapeutics Stock (APVO) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Aptevo Therapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Aptevo Therapeutics Stock (APVO) from India?

Indian investors can start investing in Aptevo Therapeutics (APVO) shares with as little as ₹96.779998779297 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹967.80 in Aptevo Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Aptevo Therapeutics share’s latest price of $1.79 as on October 10, 2026 at 8:45 am IST, you will get 5.5866 shares of Aptevo Therapeutics. Learn more about fractional shares .

What are the returns that Aptevo Therapeutics has given to Indian investors in the last 5 years?

Aptevo Therapeutics stock has given -100% share price returns and 28.36% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?